Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss
LOS ANGELES , Feb. 27, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, announced today that the company has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures, to advance a first-in-class treatment for androgenetic alopecia or pattern baldness, and other types of alopecia including chemotherapy-induced hair loss.
- Additionally, PP405 may also have applications for other types of hair loss such as telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.
- "What we've observed is that in people who experience hair loss, the actual hair follicle stem cells are still present but have reverted to a dormant state.
- "Hair loss is an incredibly common health problem with few effective solutions," said Cathy Friedman, Executive Venture Partner, GV and Board Director, Pelage Pharmaceuticals.
- Pelage is built on rigorous science and offers the opportunity to target the follicle stem cells directly," said Dr. Weng.